A two part Phase IIa Study, to Evaluate the Safety and Tolerability, Pharmacokinetics, Proof of Mechanism and Potential for Efficacy of an Anti-IL-7 Receptor-α Monoclonal Antibody (GSK2618960) in the Treatment of Primary Sjögren’s Syndrome.
- Registry ID
- EUCTR2016-004258-14
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE2
- Sponsor
- GlaxoSmithKline Research & Development Limited
- Start date
- 2017-01-13
- Completion date
- 2017-10-12
- Last update
- 2026-08-16
Conditions
- Primary Sjögren’s Syndrome
Summary
Part I
Assess safety and tolerability of repeat intravenous (IV) administration of GSK2618960.
Part II
Assess safety and tolerability of repeat IV administration of GSK2618960
Locations
View on source registry